Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus
Microbiology Spectrum · 07.10.2025 · 13 (10)
DOI: 10.1128/spectrum.01492-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 07.10.2025. Verfasst von Avneesh Shrivastava und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, Texas, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Mycobacterium abscessus, Cephalosporins, Carbapenems. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Cystic Fibrosis Foundation Therapeutics.
Abstract (Originalsprache)
Despite the long therapy duration, the treatment outcomes for Mycobacterium abscessus lung disease (MAB-LD) are very poor. β-Lactams are among the recommended drugs for the treatment of MAB-LD; however, they are prone to hydrolysis by MAB β-lactamase enzymes. Therefore, β-lactamase inhibitors have been developed to overcome this problem. Here, we performed minimum inhibitory concentration studies with a reference MAB strain (ATCC19977) and a collection of 63 clinical isolates for penicillin, cephalosporin, and carbapenems alone or in combination with β-lactamase inhibitors, sulbactam/durlobactam (Sul/Dur). There was an average 64-fold (range: 19 to 103) reduction in drugs MIC in the presence of 4 mg/L Sul/Dur (1:1 ratio). The fold reduction in MICs was as follows: amoxicillin 94, ceftriaxone 103, cefuroxime 69, cefdinir 19, cefalexin 74, imipenem 23, meropenem 37, tebipenem 89, and faropenem 74. The Sul/Dur combination also improved the kill effect of the tested β-lactams by multiple folds as follows: amoxicillin 12.6, ceftriaxone 2,872, cefuroxime 135.5, cefdinir 26.5, cefalexin 1,030, imipenem and meropenem 14, and faropenem 5.5. Since imipenem is already included in the MAB-LD treatment recommendations and ceftriaxone achieves very high lung concentration, we propose to first test these drugs with Sul/Dur as a double β-lactam-β-lactamase backbone regimen to advance the therapy for MAB-LD. IMPORTANCE β-Lactams are among the recommended drugs for the treatment of Mycobacterium abscessus lung disease (MAB-LD); however, they are prone to hydrolysis by MAB β-lactamase enzymes. We show that sulbactam/durlobactam (Sul/Dur) can improve the kill effect of several β-lactam antibiotics that, otherwise, due to observed high minimum inhibitory concentration, deem ineffective. Based on our findings, we propose imipenem that is already included in the MAB-LD treatment recommendations and ceftriaxone that achieves very high lung concentration, to test with Sul/Dur as a double β-lactam-β-lactamase backbone regimen to advance the therapy for MAB-LD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
- Undergraduate Medical Education, University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
- Section of Pulmonary and Critical Care, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, Texas, USA.
- IMPI Biotechnology Company Incorporated, Mount Hampden, Zimbabwe.
- Department of Cellular and Molecular Biology, The University of Texas Health Science Centre at Tyler, Tyler, Texas, USA.
ORCID-Profile: Sanjay Singh, Pamela J McShane, Megan Devine, Tawanda Gumbo, Shashikant Srivastava
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- Cystic Fibrosis Foundation Therapeutics
Zitieren
APA
Shrivastava, A., Boorgula, G. D., Singh, S., Stiles, D., McShane, P. J., Devine, M., Gumbo, T., & Srivastava, S. (2025). Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus. Microbiology Spectrum, 13(10). https://doi.org/10.1128/spectrum.01492-25
Vancouver
Shrivastava A, Boorgula GD, Singh S, Stiles D, McShane PJ, Devine M, et al. Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus. Microbiology Spectrum. 2025;13(10). doi:10.1128/spectrum.01492-25
BibTeX
@article{Shrivastava2025,
author = {Shrivastava, Avneesh and Boorgula, Gunavanthi D and Singh, Sanjay and Stiles, Danaleigh and McShane, Pamela J and Devine, Megan and Gumbo, Tawanda and Srivastava, Shashikant},
title = {Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus},
journal = {Microbiology Spectrum},
year = {2025},
volume = {13},
number = {10},
doi = {10.1128/spectrum.01492-25}
}
EUVIMED